Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
All week long we’ve been meaning to write an item about an ad we saw in which a law firm chasing Vioxx lawsuits also mentioned another drug in the same class, Pfizer’s Bextra, in the same breath—as though it were as bad.
At the time, it seemed like piling on—not that there should be anything surprising about that, coming from personal injury lawyers—because the evidence about problems associated with Bextra wasn’t nearly so damning, and it hasn’t been yanked from the market.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in